Safety and Efficacy of Clobazam in Lennox-Gastaut Syndrome

Phase 2, randomised, double-blind trial of clobazam in Lennox-Gastaut syndrome (LGS) (2 arms), sponsored by Lundbeck. Primary endpoints: Percent Reduction in Number of Drop Seizures at 4 weeks and Comparison of the High Dose Group to Low Dose Group of the Percent Reduction in Number of Drop Seizures at 4 weeks. Started Oct 2005; status: completed.